Berlin, Germany, Seattle, WA, and Lexington, MA, U.S.A., January 29, 2013 - Epigenomics AG
(Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company,
and Predictive Biosciences, an innovative developer of molecular diagnostic tests, today
announced that Predictive Biosciences of Lexington, MA, has made commercially available a
novel tissue-based test for prostate cancer biopsy confirmation utilizing Epigenomics’ proprietary
DNA methylation marker GSTP1.
Pierre Cassigneul, Chief Executive Officer of Predictive Biosciences, stated: “We are excited to
build upon our existing CertNDx™ commercial franchise in bladder cancer, with the first of
several novel tests we plan to commercialize over the next few years which will address the
significant unmet diagnostic clinical needs in prostate cancer”.
Additionally, Noel Doheny, Chief Executive Officer of Epigenomics’ US subsidiary,
commented: “We are pleased that Predictive Biosciences has successfully moved forward to
introduce their assay based on Epigenomics’ intellectual property into the market. This further
demonstrates the growing importance of DNA methylation based tests in cancer diagnostics”.
Contact Epigenomics AG
Manager IR | PR
Tel +49 (0) 30 24345 368
About Predictive Biosciences
Predictive Biosciences develops novel molecular diagnostic cancer assays and provides
molecular pathology services for urology-based practices. Leveraging a portfolio of patented
biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer
management, first targeted at bladder and prostate cancer. For additional information, please visit
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and
commercializing a pipeline of proprietary products for cancer. The Company’s products enable
doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for
patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection
of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A.
The Company’s technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements
concerning Epigenomics AG and its business. Such statements involve certain known and
unknown risks, uncertainties and other factors which could cause the actual results, financial
condition, performance or achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or
transfer any product, and no product based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which may be sold at some
future time in the U.S. have not been established.